选择性雌激素受体修饰剂对青少年大鼠中电发作类似抗抑郁药的影响
Celia Garau1,2, Sandra Ledesma-Corvi1,2, Yaiza Jiménez-Marín1,2
1IUNICS, University of the Balearic Islands, Palma, Spain.
Translational psychiatry
|February 18, 2026
概括
塔莫西芬通过改善行为和神经可塑性,增强了青少年大鼠中电发作 (ECS) 抗抑郁药的效果. 克洛米芬没有表现出类似的益处,这表明他莫西芬.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 电发作 (ECS) 在动物早期生活压力模型中显示出性别和年龄相关的抗抑郁药效果.
- 雌激素生物合成抑制 (莱特醇) 改善了青少年雌性大鼠的ECS疗效,这表明性激素的作用.
- 选择性雌激素受体修饰剂 (SERM) 需要进行研究,以提高ECS抗抑郁药的潜力.
研究的目的:
- 评估塔莫西芬和克洛米芬与ECS诱导的青少年雄性和雌性大鼠抗抑郁药类反应的相互作用.
- 评估SERM对行为抗抑郁药类活性和海马神经可塑性标记物的影响.
- 确定SERM在青少年动物中增强ECS抗抑郁疗效的潜力.
主要方法:
- 在青春期,患有早期压力Sprague-Dawley大鼠 (母体分离) 在青春期接受了他莫西芬或克洛米芬的治疗.
- 动物在连续五天内接受电发作 (ECS) 治疗.
- 使用强迫游泳测试和分析海马体标志物 (细胞增殖,神经元分化,BDNF蛋白水平) 来测量类似抗抑郁药物的反应.
主要成果:
- 塔莫西芬的使用改善了青少年大鼠对ECS的抗抑郁药类反应,这是强迫游泳测试中的行为结果证明的.
- 塔莫西芬治疗也促进了海马细胞的增殖和神经元分化.
- 克洛米芬没有改变对ECS的行为反应,并且对神经元分化和BDNF水平产生了负面影响.
结论:
- 塔莫西芬在青少年人群中显示出作为辅助疗法的潜力,以增强ECS的抗抑郁药类效应.
- 塔莫西芬对行为和神经可塑性的积极影响表明,它可能是改善ECS治疗结果的有希望的选择.
- 克洛米芬没有产生有益的效果,因此需要进一步研究其对神经可塑性标记物的影响.
相关概念视频
01:30Electroconvulsive Therapy
1.4K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.4K
01:23Antidepressant Drugs: MAOIs and Other Agents
975
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
975
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.7K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.7K
01:25Antidepressant Drugs: Overview
1.7K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.7K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
968
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
968